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Abstract
Background: There is no clear relationship between in vitro bactericidal activity tests and clinical outcome. We
studied bactericidal activity of oxacillin, vancomycin and teicoplanin against Staphylococcus aureus isolates in
patients with endocarditis and then we sought to determine if there was a relationship between in vitro
bactericidal activity and clinical outcome.
Methods: Minimal bacteriostatic and minimal bactericidal concentrations were determined for Staphylococcus
aureus strains isolated from patients with endocarditis following standardized methods. Medical records were
reviewed retrospectively to collect data on antimicrobial susceptibility at admission, antimicrobial therapy, need for
surgery, embolic events and outcome.
Results and Discussion: Sixty-two Staphylococcus aureus strains were studied in 62 patients with endocarditis.
Overall, 91.9% definite, 21% methicillin resistant and 72.6% cured. Surgery was performed in 32.3% and embolic
events were documented in 64.5%. Tolerance to oxacillin and teicoplanin was more common than vancomycin
tolerance among methicillin susceptible Staphylococcus aureus. Among methicillin resistant Staphylococcus aureus
teicoplanin was shown to have a higher rate of tolerance than vancomycin. No statistically significant differences
on clinical outcome between oxacillin tolerant and oxacillin non tolerant Staphylococcus aureus infections were
observed. Tolerance to oxacillin did not adversely affect clinical outcomes of patients with methicillin susceptible
Staphylococcus aureus endocarditis treated with a combination of antimicrobials including oxacillin. The cure rate
was significantly lower among patients with methicillin resistant Staphylococcus aureus endocarditis.
Conclusions: In vitro bactericidal test results were not valid predictors of clinical outcome. Physicians need to use
additional parameters when treating patients with staphylococcal endocarditis.
Background
In recently published surveys Staphylococcus aureus (S.
aureus) is reported to overstep viridans Streptococci as a
cause of endocarditis (IE) and associated morbidities and
mortality [1,2]. S.aureus is an extraordinarily adaptable
bacterium, developing increasing patterns of resistance
which contribute to clinical failures. Penicillin resistance
was soon followed by methicillin resistance, which always
includes resistance to all beta-lactam antimicrobials and
often to several other classes of antibiotics [3]. The effi-
cacy of vancomycin against methicillin resistant S.aureus
(MRSA) has been reported to be inferior to that of beta-
lactams against methicillin susceptible S.aureus (MSSA)
due to its slower in vitro bactericidal activity with a lower
clinical response [4-6]. Recently other reasons for the
clinical failure of vancomycin have been indicated and
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mum inhibitory concentrations (MICs) over time, but
with values still in the susceptibility range, and the emer-
gence of S.aureus showing either glycopeptide hetero-
resistance, an intermediate level of resistance (GISA) or
full resistance (GRSA) [7-10].
Tolerance is another form of antimicrobial resistance
of S.aureus hypothesised to be a cause of clinical failure.
Tolerance has been described for anti-staphylococcal
beta-lactams but involves also glycopeptide antimicrobial
agents. There have been studies reporting infections
caused by tolerant strains more difficult to eradicate and
antimicrobial regimens with bactericidal activity superior
to that of bacteriostatic regimens in the treatment of
serious S.aureus infections. Tolerant strains are suscepti-
ble as judged by MICs but show an increasing resistance
to the killing with high minimal bactericidal concentra-
tions (MBCs) and an MIC/MBC ratio≥32. Bactericidal
activity can also be evaluated with time killing curves
but, independently from the method used, there are the-
oretical and technical difficulties in performing these
tests. Thus, highly standardised methods should be fol-
lowed. To date, bactericidal activity has been regarded
as a desirable characteristic in antimicrobial agents
when treating patients with endocarditis, while, routine
MBC testing is not recommended because of the techni-
cal difficulties associated with these tests [11-15].
The aims of this study were:
a) To determine the in vitro bactericidal activity of
oxacillin, vancomycin and teicoplanin against S.aureus
isolated in patients with S.aureus endocarditis
b) To look for a relationship between in vitro bacter-
icidal activity and clinical outcome using data avail-
able from patients that had been previously enrolled
in observational studies on endocarditis.
Methods
Isolates of S.aureus were collected from patients with IE
admitted to the Infectious Disease Departments (IDD) of
Perugia and Bergamo from 1988-2009. A total of 30
strains were from Perugia and 32 from Bergamo. The
initial blood isolates on the day of admission were stored
at -70°C until the time of in vitro testing. MICs and MBCs
were determined at the IDD of Perugia under blinded con-
ditions according to CLSI guidelines [16-18].
1) Oxacillin: Cefoxitin disk diffusion using Muller-Hin-
ton agar plates (bioMerieux) and 30 μg cefoxitin disk
(bio-Merieux) and interpreted according to CLSI break
points (16), macro-method MIC using Muller Hinton
Broth (MHB), inoculum 1-5 × 10
5 CFU/ml, stationary
phase of growth) (17) and E-test MIC according to the
E-test manufacturer (AB Biodisk).
2) Vancomycin: macro-method MIC (MHB, inoculum
1-5 × 10
5 CFU/ml, stationary phase of growth) (17) and
E-test MIC.
3) Teicoplanin: macro-method MIC (MHB, inoculum
1-5 × 10
5 CFU/ml, stationary phase of growth) (17),
E-test MIC.
MBC was determined by sub-culturing 50 μl from each
vial without a visible growth onto plates of Muller Hin-
ton agar (MHA), after 24h of incubation at 35°C. The
geometric mean of duplicate colony counts were used to
determine the MBC defined as the antibiotic concentra-
tion with killing of 99.9% of the initial inoculum (18). In
the presence of Eagle phenomenon, MBC was the anti-
biotic concentration yielding persistent killing of 99.9% of
the initial inoculum.
MIC50 and MIC90 were determined by interpolation
from graphs of cumulated percent strains inhibited ver-
sus MIC [19].
MSSA ATCC 29213 was used as a control strain in all
these experiments.
Medical records of each patient were reviewed retro-
spectively to collect data on: demographic data, year of
diagnosis, valve localization, hospital or community
acquired infection, antimicrobial susceptibility results at
the time of patient admission and antimicrobial treat-
ment, surgery, embolic events and outcomes.
There was no research related effect for patients.
Patients gave informed consent to be included in the
observational protocol on endocarditis cases. The proto-
col was approved by the institutional ethical committee
of Perugia and Bergamo. All activity was conducted in
accordance with the Declaration of Helsinki, and
national and institutional review board.
Associations among qualitative variables were analysed
using the contingency table. The statistical significance
was assessed with the Fisher exact test.
Results
Sixty-two isolates of S.aureus were collected from
patients with endocarditis, 58% male, 91.9% definite
(DE) and 8.1% possible (PE) according to Duke criteria,
47 (75.8%) native valve endocarditis (NVE) and 15
(24.2%) prosthetic valve endocarditis (PVE), three pace-
maker wire (PM) infections and 37% hospital acquired.
Overall, 13/62 (21%) were caused by MRSA and 76.9 of
these were hospital acquired. All the isolates were
reported vancomycin and teicoplanin susceptible. Over-
all, 45 patients (72.6%) were cured and 17 (27.4%) died
of endocarditis. Surgery was performed on 20 (32.3%)
and embolic events were documented in 40 cases
(64.5%) (Table 1).
Oxacillin, vancomycin and teicoplanin susceptibility of
62 S.aureus isolates are reported in Table 2. Oxacillin
and teicoplanin results in this study were in agreement
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comycin susceptibility was not fully confirmed for two
isolates tested. One of these was cultured from a patient
in Bergamo and one from Perugia; both had macro-
method MICs of 4 mg/l while their MICs with the
E-test were 2.5 mg/l and 2.0 mg/l respectively.
Methicillin resistance was confirmed in 13 out of 62
(21%) isolates.
MSSA susceptibility tests: oxacillin geometric mean
MIC 0.52 mg/l (range 0.25-1), MIC50 0.35 mg/l, MIC90
0.48 mg/l, tolerance rate 63.2%; vancomycin mean MIC
1.69 mg/l (range 1-2), MIC50 1.1 mg/l, MIC90 1.7 mg/l,
tolerance rate 18.4%; teicoplanin mean MIC 1.39 mg/l
(range 1-2), MIC50 0.9 mg/l, MIC90 1.7 mg/l, tolerance
rate 61.2%.
MRSA susceptibility tests: vancomycin mean MIC
2.3 mg/l (range 2-4), MIC50 1.5 mg/l, MIC90 2.5 mg/l,
tolerance rate 30.8%; teicoplanin mean MIC 2.1 mg/l
(range 1-4), MIC50 1.3 mg/l, MIC90 2.5 mg/l, tolerance
rate 76.9% (Table 3).
Among the 31 oxacillin tolerant strains, 8 (26%) were
also vancomycin tolerant and 18 (58%) were teicoplanin
tolerant. Only one of the oxacillin non tolerant isolates
was vancomycin tolerant while 12 (66%) were tolerant
to teicoplanin.
Antimicrobial susceptibility tests had been performed
at local laboratories at the time of diagnosis, as well,
treatment had been decided by the curing physicians
on the basis of available susceptibility results and the
clinical conditions of patients. MSSA IE antimicrobial
therapy consisted of: oxacillin 37, cefazolin 5, vanco-
mycin 4, teicoplanin 1 and not known 2. MRSA IE (13
cases) were treated with vancomycin 10, teicoplanin 1
and in 2 therapy was not known. Beta-lactam or glyco-
peptide antimicrobials were administered in combina-
tion with rifampin or an aminoglycoside, or a
quinolone or a combination of two or more of these
antimicrobials for MSSA and MRSA in most of the
cases. Need for surgery had been individualised follow-
ing international indications. Overall, the cure rate was
79.6% for MSSA: 31 oxacillin, 4 cefazolin, 3 vancomy-
cin and 1 teicoplanin while the cure rate for MRSA
was 46.2%: 5 vancomycin and 1 unreported treatment
(p < 0.032). There was no evidence of any differences
with regard to need for surgery or embolic events
between MSSA and MRSA IE (Table 4). There were
only four patients with MRSA IE vancomycin tolerant
and all of these had been treated with antimicrobial
combinations including vancomycin and had a cure
rate of 25% (Table 4).
Table 1 Epidemiology of S.aureus endocarditis
Year Total DE (%) NVE (%) PVE (%) PM MRSA (%) HA (%) SUR (%) EMB (%) Cured (%)
≤2000 4 4 3 1 0 0 0 2 4 3
2001 3 3 3 0 0 1 2 3 2 3
2002 1 1 1 0 0 0 0 0 1 1
2003 1 1 1 0 0 1 1 0 1 0
2004 5 5 4 1 2 0 1 2 1 4
2005 14 14 12 2 0 2 5 5 9 11
2006 12 11 9 3 1 3 7 6 10 10
2007 3 3 2 1 0 0 1 0 2 0
2008 5 4 2 3 0 2 2 1 2 4
2009 14 11 10 4 0 4 4 1 8 9
Total 62 57 (91.9) 47 (75.8) 15 (24.2) 3 13 (21.0) 23 (37.0) 20 (32.3) 40 (64.5) 45 (72.6)
DE (definite endocarditis, NVE (native valve endocarditis), PVE (prosthetic valve endocarditis), PM (pace maker), HA (hospital acquired), SUR (surgery), EMB
(embolism).
Table 2 Bacteriostatic activity of oxacillin and glycopeptides
Antibiotics Macromethod MICs N.susceptible/N.tested (%) E-test MICs N.susceptible/N.tested (%)
□Oxacillin (MIC: S≤2 mg/l) (DISK:S≥22 mm) 49/62 (79.0%) 49/62 (79.0%)
*/**Vancomycin (S≤2 mg/l) 60/62 (96.7%) 61/62 (98.3%)
*Teicoplanin (S≤8 mg/l) 62/62 (100%) 62/62 (100%)
**Teicoplanin (S≤2 mg/l) 60/62 (96.7%) 60/62 (96.7%)
□ CLSI and EUCAST susceptibility break point, cefoxitin disk diffusion same results as oxacillin
*CLSI susceptibility break point
**EUCAST susceptibility break point
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Page 3 of 7Table 3 MIC geometric mean, MIC50, MIC90 and rate of tolerance (macromethod)
Oxacillin Vancomycin Teicoplanin
Mean MIC (mg/l)
(range)
MIC 50
(mg/l)
MIC90
(mg/l)
N.tolerant
(%)
Mean MIC (mg/l)
(range)
MIC 50
(mg/l)
MIC90
(mg/l)
N. tolerant
(%)
Mean MIC (mg/l)
(range)
MIC 50
(mg/l)
MIC90
(mg/l)
N. tolerant
(%)
MSSA N.49
(79%)
0.52 (0.25-1) 0.35 0.48 31/49
(63.2%)
1.69 (1-2) 1.1 1.7 9/49 (18.4%) 1.39 (1-2) 0.9 1.7 30/49
(61.2%)
MRSA N.13
(21%)
NA NA NA NA 2.3 (2-4) 1.5 2.5 4/13 (30.8%) 2.1 (1-4) 1.3 2.5 10/13
(76.9%)
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7A negative effect of oxacillin tolerance was not
observed either in the entire subgroup of IE cases
caused by MSSA or in the subgroup of patients with
MSSA IE being treated with an antibiotic regimen con-
taining oxacillin (Table 5).
Discussion
This study was designed to assess the rate of tolerance
to oxacillin, vancomycin and teicoplanin among S.aureus
isolates in patients with IE. Thereafter, we sought to
determine a relationship between in vitro bactericidal
tests and clinical outcome.
The bactericidal test results of this study, defined by
MBCs, showed that vancomycin bactericidal activity was
not inferior to that of oxacillin and teicoplanin against
MSSA. Glycopeptide tolerance was more common
among MSSA oxacillin tolerant strains but a few non
tolerant MSSA oxacillin with high MBC for glycopep-
tides were also observed.
Among MRSA isolates, vancomycin tolerance rate was
inferior to that of teicoplanin and all the 4 vancomycin
tolerant isolates were also teicoplanin tolerant.
Previous papers have reported that vancomycin has in
vitro bactericidal activity slower than that of nafcillin
with more frequent clinical failures in animal models
and also patients being treated with vancomycin [4-6].
Technical variables such as inoculum size, growth con-
ditions and killing curves, instead of MBCs, may be
responsible for some of the differences in the results of
this study. May et al. [20] found MBCs and the killing
rates comparable with some discrepancies. Lack of kill-
ing in vitro has also been hypothesised to be a reversible
phenotypic response due to growth conditions of the
test with some types of constitutional changes noted in
tolerant strains [21,22]. It has been reported that most
beta-lactam tolerant strains of S.aureus show cross tol-
erance to vancomycin and teicoplanin [23].
Regarding clinical outcome, 79% of IE cases in this
study were caused by MSSA. In these patients, oxacillin
was the most common antibiotic prescribed and it was
usually given in combination with other antibiotics in
both oxacillin tolerant and oxacillin non-tolerant MSSA
infections. Analysis was unable to demonstrate either
increased mortality or morbidity in oxacillin tolerant
MSSA IE patients. Strikingly, a non-statistically signifi-
cant higher cure rate was observed in patients with IE
caused by oxacillin tolerant MSSA in both the entire
MSSA IE group and in the MSSA subgroup treated with
oxacillin.
Despite its greater in vitro bactericidal activity, a
higher rate of clinical failures was observed among
patients with MRSA IE. Among MRSA IE patients,
higher rates of clinical failure were observed among
patients with endocarditis caused by vancomycin toler-
ant MRSA strains, but there were only four patients in
this group of patients to comment on.
With regard to bacteriostatic activity, methicillin resis-
tance was confirmed in 21% of the isolates. Methicillin
resistance occurred more commonly among hospital
acquired infections with the exception of three cases.
One of these should be classified as health care asso-
ciated even though the isolate had a mecA cassette type
V, which is a marker for methicillin-resistant commu-
nity acquired infection [24] and was susceptible to all
other classes of antibiotics except penicillin. This patient
reported a traumatic tibia fracture, was treated with
external devices and discharged from hospital. Subse-
quently, the patient developed osteomyelitis and
Table 5 Rates of cure, surgery, and embolism in MSSA endocarditis caused by oxacillin tolerant and oxacillin non-
tolerant strains
MSSA 49/62 (79%) Cured N. (%) Surgery N. (%) Embolic events N. (%)
Oxacillin tolerant N. 31 (63.2%) 26/31 * (83.9%) 10/31 ** (32.3%) 21/31 ** (67.7%)
Oxacillin non tolerant N. 18 (36.8%) 13/18 * (72.2%) 6/18 ** (33.3%) 12/18 ** (66.7%)
MSSA oxacillin tolerant treated with oxacillin/total MSSA oxacillin tolerant N.
24/31 (77.4%)
21/24 °(87.5%) - -
MSSA oxacillin non tolerant treated with oxacillin/total MSSA oxacillin non-
tolerant N. 13/18 (72.2%)
10/13 °(76.9%) - -
*p = 0.46, **p = 1, °p = 0.64
Table 4 Rates of cure, surgery, and embolism in endocarditis caused by MSSA and MRSA
Cured N. (%) Surgery N. (%) Embolic events N. (%)
MSSA N. 49 (79%) 39/49 *(79.6%) 16/49 ** (32.7%) 33/49 *** (67.3%)
MRSA N. 13 (21%) 6/13 *(46.2%) 4/13 ** (30.8%) 7/13 *** (53.8%)
Vancomycin tolerant N. 4/13 (30.8%)
Vancomycin non tolerant N. 9/13 (69.2%)
1/4 °(25,0%)
5/9 °(55,5%)
*p < 0.032, **p = 1, ***p = 0.51, °p = 0.55.
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Page 5 of 7endocarditis with multiple septic lung emboli and myo-
cardial abscess. The other two cases were community
acquired MRSA IE from the Bergamo cohort.
Concordant susceptibility test results were obtained
also with teicoplanin.
With regard to vancomycin, there was no full agreement
on the grade of susceptibility obtained at admission. Two
isolates had vancomycin macro-method MICs of 4 mg/l,
which are intermediate suscept i b l ev a l u e s .T h eo b t a i n e d
values were still in the susceptible range when performing
the E-test, being 2 mg/l for the Perugia isolate and 2.5 mg/l
for the Bergamo isolate. The former was methicillin resis-
tant, hospital acquired, non tolerant to vancomycin but tei-
coplanin tolerant, cultured in early prosthetic infection
with valve abscess. The patient treatment included teico-
planin, followed by daptomycin and rifampin then tigecy-
cline. The patient died. The latter isolate was methicillin
resistant, hospital acquired and vancomycin tolerant, cul-
tured from a case of pace-maker infection. The patient
underwent both the surgical removal of the device and
vancomycin plus fosfomicin and co-trimoxazole treatment
with cure.
In this study, all 62 isolates had slightly higher macro-
method vancomycin MICs than with the E-test. Pre-
viously in literature, higher vancomycin MICs have been
observed with the E-test compared to the micro-dilution
method. Nonetheless, the micro-dilution method and E-
test both have been reported to perform differently than
disk diffusion and some automated systems [25,26].
Given this, while these in vitro vancomycin susceptibility
testing parameters are being standardised, it may be
advisable to assess vancomycin MICs with more than
one method and to carry out a close clinical and micro-
biological follow up while the patients are being treated
with vancomycin.
A progressive increase in vancomycin MICs over time
was not observed in this study [7,25,26] however, there
were very few strains included before the year 2004 and
all of these, though methicillin susceptible, already had
vancomycin MIC of 1-2 mg/l.
Conclusions
This study reports that oxacillin and teicoplanin toler-
ance was common among S.aureus and more common
than vancomycin. This study was unable to show a
statistically significant correlation between bactericidal
activity in vitro and clinical outcome. However, one
must consider that these results were from a retro-
spective analysis and treatment was not standardized.
Additional, prospective standardized studies are
needed to evaluate if in vitro bactericidal tests are
valid predictors of clinical outcome in staphylococcal
endocarditis.
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